Liu, Stephanie N.Gufford, Brandon T.Lu, Jessica Bo LiBushman, Lane R.Anderson, Peter L.Bergstrom, Richard F.Desta, ZeruesenayGupta, Samir K.2020-01-232020-01-232019Liu, S. N., Gufford, B. T., Lu, J. B. L., Bushman, L. R., Anderson, P. L., Bergstrom, R. F., … Gupta, S. K. (2019). Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Pre-Exposure Prophylaxis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.1714https://hdl.handle.net/1805/21885In a randomized, crossover pharmacokinetic study in healthy volunteers (N = 14), a single dose of 2 g probenecid (PRO)‐boosted 600 mg tenofovir disoproxil fumarate (TDF)/400 mg emtricitabine (FTC) (test (T) +PRO) was compared with the current on‐demand HIV preexposure prophylaxis from the IPERGAY study (a 600 mg TDF/400 mg FTC on day 1 and 300 mg TDF/200 mg FTC on days 2 and 3) (control, C IPERGAY). PRO increased mean single‐dose area under the plasma concentration‐time curve extrapolated to infinity (AUC0–∞,SD) of tenofovir (TFV) and FTC by 61% and 68%, respectively. The TFV‐diphosphate (TFV‐DP) concentrations in peripheral blood mononuclear cells were higher (~30%) at 24 hours in T +PRO but then fell significantly lower (~40%) at 72 hours compared with C IPERGAY. The interaction between FTC and PRO was unexpected and novel. Further study is needed to determine if this PRO‐boosted TDF/FTC regimen would be clinically effective.enPublisher PolicyHIVpre-exposure prophylaxisprobenecidArticle